Relugolix Clinical Trials
10 actively recruiting trials across 9 locations
▲ +1 trial since May 2026
Also known as: N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, Relumina, TAK 385, TAK-385 +3 more
Pipeline
Top Sponsors
- Mayo Clinic2
- Qilu Pharmaceutical Co., Ltd.1
- Ohio State University Comprehensive Cancer Center1
- Northwestern University1
- Emory University1
Indications
- Cancer10
- Prostate Adenocarcinoma4
- Heart Disease2
- Stage IIC Prostate Cancer AJCC v82
- Biochemically Recurrent Prostate Carcinoma2
Other1 trial
Anchorage, Alaska1 trial
Anchorage Associates in Radiation Medicine
Phoenix, Arizona1 trial
Scottsdale, Arizona1 trial
Miami, Florida1 trial
Miami Cancer Institute at Baptist Health, Inc.
Orlando, Florida1 trial
AdventHealth Orlando
Atlanta, Georgia1 trial
Emory Proton Therapy Center
Chicago, Illinois1 trial
Boston, Massachusetts1 trial
Brigham and Women's Hospital
Columbus, Ohio1 trial
Ohio State University Comprehensive Cancer Center
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.